Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    August 2022
  1. HUTTER JN, Robben PM, Lee C, Hamer M, et al
    First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naive adults.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01039.
    >> Share

    June 2022
  2. SCHNEIDER CG, Fey J, Zou X, Gerbasi V, et al
    Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00701.
    >> Share

    January 2022
  3. AREVALO-HERRERA M, Miura K, Solano E, Sebastian Ramirez J, et al
    Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.
    Vaccine. 2022;40:133-140.
    >> Share

    December 2021
  4. KUSI KA, Ofori EA, Akyea-Mensah K, Kyei-Baafour E, et al
    Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01650.
    >> Share

  5. RANADE D, Jena R, Sancheti S, Deore V, et al
    Rapid, high throughput protein estimation method for saponin and alhydrogel adjuvanted R21 VLP Malaria vaccine based on intrinsic fluorescence.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01627.
    >> Share

    September 2021
  6. MOON JE, Greenleaf ME, Regules JA, Debois M, et al
    A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01203.
    >> Share

    June 2021
  7. DASSAH S, Adu B, Sirima SB, Mordmuller B, et al
    Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00760.
    >> Share

    April 2021
  8. VEKEMANS J, Schellenberg D, Benns S, O'Brien K, et al
    Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00409.
    >> Share

  9. DE SL, May S, Shah K, Slawinski M, et al
    Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00376.
    >> Share

    February 2021
  10. DAS SC, Price JD, Gosling K, MacLennan N, et al
    Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00158.
    >> Share

    January 2021
  11. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Cox C, et al
    Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31590.
    >> Share

  12. CHAUDHURY S, MacGill RS, Early AM, Bolton JS, et al
    Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31635.
    >> Share

    December 2020
  13. SUAU R, Vidal M, Aguilar R, Ruiz-Olalla G, et al
    RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31606.
    >> Share

    October 2020
  14. MO AXY, Pesce J, Augustine AD, Bodmer JL, et al
    Understanding vaccine-elicited protective immunity against pre-erythrocytic stage malaria in endemic regions.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31253.
    >> Share

  15. THOMPSON HA, Hogan AB, Walker PGT, White MT, et al
    Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31251.
    >> Share

  16. EZOE S, Palacpac NMQ, Tetsutani K, Yamamoto K, et al
    First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
    Vaccine. 2020 Oct 1. pii: S0264-410X(20)31227.
    >> Share

    September 2020
  17. VAN DER GRAAF R, Macklin R, Rid A, Bhan A, et al
    Integrating public health programs and research after the malaria vaccine implementation program (MVIP): Recommendations for next steps.
    Vaccine. 2020 Sep 24. pii: S0264-410X(20)31132.
    >> Share

    June 2020
  18. SCARIA PV, Chen BB, Rowe CG, Alani N, et al
    Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
    Vaccine. 2020 Jun 26. pii: S0264-410X(20)30790.
    >> Share

  19. OUATTARA A, Niangaly A, Adams M, Coulibaly D, et al
    Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30821.
    >> Share

  20. CHEUNG YB, Ma X, Lam KF, Milligan P, et al
    Estimation of the primary, secondary and composite effects of malaria vaccines using data on multiple clinical malaria episodes.
    Vaccine. 2020 Jun 11. pii: S0264-410X(20)30753.
    >> Share

    May 2020
  21. ONEKO M, Cherop YR, Sang T, Gutman JR, et al
    Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya.
    Vaccine. 2020 May 19. pii: S0264-410X(20)30614.
    >> Share

  22. NOUATIN O, Ateba Ngoa U, Ibanez J, Dejon-Agobe JC, et al
    Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults.
    Vaccine. 2020 May 5. pii: S0264-410X(20)30540.
    >> Share

    April 2020
  23. BELL GJ, Loop M, Topazian HM, Hudgens M, et al
    Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
    Vaccine. 2020 Apr 30. pii: S0264-410X(20)30511.
    >> Share

    March 2020
  24. TACHIBANA M, Baba M, Takashima E, Tsuboi T, et al
    The C-terminal region of the Plasmodium yoelii microgamete surface antigen PyMiGS induces potent anti-malarial transmission-blocking immunity in mice.
    Vaccine. 2020;38:3129-3136.
    >> Share

  25. ASANTE KP, Ansong D, Kaali S, Adjei S, et al
    Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.
    Vaccine. 2020 Mar 16. pii: S0264-410X(20)30358.
    >> Share

    February 2020
  26. QIU Y, Zhao Y, Liu F, Ye B, et al
    Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.
    Vaccine. 2020 Feb 21. pii: S0264-410X(20)30184.
    >> Share

  27. SSEMAGANDA A, Giddam AK, Low LM, Liu XQ, et al
    Mannosylated liposomes formulated with whole parasite P. falciparum blood-stage antigens are highly immunogenic in mice.
    Vaccine. 2020;38:1494-1504.
    >> Share

    November 2019
  28. OTIENO L, Guerra Mendoza Y, Adjei S, Agbenyega T, et al
    Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Vaccine. 2019 Nov 7. pii: S0264-410X(19)31466.
    >> Share

    February 2019
  29. KINGSTON NJ, Kurtovic L, Walsh R, Joe C, et al
    Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Vaccine. 2019 Feb 14. pii: S0264-410X(19)30132.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016